Last updated 3 days ago
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
150 patients around the world
Available in United States, Chile
Merck Sharp & Dohme LLC
4Research sites
150Patients around the world
This study is for people with
Malignant neoplasm
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- The main inclusion criteria include but are not limited to the following.Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment.Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation.
- The main exclusion criteria include but are not limited to the following.Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.Has known additional malignancy that is progressing or has required active treatment within the past 3 years.Has known active central nervous system metastases and/or carcinomatous meningitis and/or primary brain tumors.Has active infection, other than those permitted per protocol, requiring systemic therapy.Has not adequately recovered from major surgery or has ongoing surgical complications.
Sites
Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Recruiting
Instituto Oncológico FALP (Fundación Arturo López Pérez)
Recruiting
Centro de Oncología de Precisión - Santiago de Chile
Recruiting
Clínica San Carlos de Apoquindo - Red de Salud UC Christus
Recruiting
StudyKANDLELIT-014
SponsorMerck Sharp & Dohme LLC
Study typeInterventional
Conditions
Malignant neoplasm
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07209111
